Multiple Myeloma - A New Era of Treatment Strategies

Indexed in: Book Citation Index, Science Edition (BKCI-S), Web of Science, Scopus, EBSCO.

Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

Guideline to Multiple Myeloma Treatment Strategies

Pp. 73-87 (15)

DOI: 10.2174/978160805297411201010073

Author(s): Klaus Podar, Jonathan L. Kaufmann, Jacob P. Laubach, Sagar Lonial, Paul G. Richardson, Kenneth C. Anderson


Multiple Myeloma (MM) is a clonal plasma cell malignancy with a highly heterogeneous genetic background, characterized by bone marrow (BM) plasmacytosis, production of monoclonal proteins, osteolytic bone lesions, renal disease, anemia, hypercalcemia, and immunodeficiency. The inclusion of thalidomide, bortezomib, and lenalidomide into conventional cytotoxic and transplantation regimens, first in relapsed and refractory and now also in newly diagnosed MM, has fundamentally changed treatment in MM during the last decade and steadily improved MM patient outcome.


Clinical features, monoclonal gammopathy of unknown significance (MGUS), smoldering multiple myeloma (SMM), CRAB, staging (Durie-Salmon, International Staging System), upfront therapy, autologous stem cell transplantation (ASCT), maintenance therapy, salvage therapy, bone disease.